← Sites

711 (USA)

USA PI: Dr. Jansen activated KRI 0.0
Patients
12
Active (enrolled/consented)
0
Withdrawn
0
Serious AEs
0
Open QA findings
0
Aged data queries
0

Studies & contracts total budget 159000.00 USD

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
Phase II study completed contract executed 159000 USD

Patients first 12

RefStatusConsentedStudy
711-1012 completed 2013-04-03 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
711-1022 screened Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
711-1036 completed 2012-07-29 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
711-1143 completed 2013-04-03 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
711-1163 screened Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
711-1173 screened Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
711-1226 screened Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
711-1251 screened Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
711-1283 screened Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
711-1284 screened Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
711-1290 screened Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.
711-1433 completed 2013-01-27 Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease.

Luna participants (0)

No participants at this site use Luna yet.

Safety 28 AEs · 0 serious

No serious adverse events at this site.

QA findings 0 open

No findings recorded.

Monitoring visits (0)

No visits recorded.

Payments (0)

No payments on file.